Hepatocellular Carcinoma
Conditions
Keywords
Secondary surveillance of hepatocellular carcinoma, Contrast enhanced liver CT, non-contrast abbreviated MRI
Brief summary
This prospective multicenter study aimed to compare the diagnostic performance of non-contrast abbreviated MRI in detecting recurrent HCC after curative treatment to that of contrast-enhanced liver CT.
Detailed description
This study was designed as a prospective single-arm intra-individual comparison multicenter study
Interventions
DIAGNOSTIC_TESTnon-contrast abbreviated MRI
Liver MRI without contrast injection. The following sequences will be obtained from all of the participants. * Axial heavily and regular T2 WI * precontrast fat-suppressed T1 WI * Diffusion-weighted image using b-value of 0, 50 or 400, and 800 or 1000
DIAGNOSTIC_TESTContrast enhanced liver CT
Liver CT with iodine contrast injection This test will be served as a standard diagnostic test. The following phases will be obtained * precontast, arterial phase, portal venous phase and delayed phase
Sponsors
Seoul National University Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 85 Years
Inclusion criteria
* Age between 20-year old and 85-year old * Patients with a history of curative treatment for HCC including surgical resection or local ablation * No recurrence after curative treatment of HCC for more than two years * Patient who has the plan to perform contrast-enhanced liver CT for secondary surveillance for HCC (i.e., to detect de novo or recurrent HCC)
Exclusion criteria
* Estimated GFR less than 60 * Previous history of severe allergic reaction to the iodinated contrast agent * Patients with claustrophobia who can't undergo MR examination * Patients having cochlear implants or cardiac pacemaker
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Accuracy per patient | Within 6 months from the study completion | Accuracy for detection of recurrent HCC per patient |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Specificity per patient | Within 6 months from the study completion | Specificity for detection of recurrent HCC per patient |
| Sensitivity per patient | Within 6 months from the study completion | Sensitivity for detection of recurrent HCC per patient |
Countries
South Korea
Outcome results
None listed